Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Generate Biomedicines Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, DRISCOLL, MAUREEN VARINA, who is the busiest examiner with 1 pending office action. This indicates that the entire pending portfolio is currently subject to the review of a single individual, making their examination style critical to the company's immediate patent goals. For the practitioner, this means there are no other active matters to provide a broader perspective on the art unit's current standards.
The prosecution is limited to 1 distinct art unit. This reflects a highly focused patenting effort where the company's current interaction with the patent office is limited to a single examiner and a single technical group. This lack of distribution across different art units or examiners suggests a highly specialized invention that falls squarely within a single regulatory niche, requiring a focused and consistent legal approach during prosecution to overcome any rejections issued by the assigned examiner in this case.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DRISCOLL, MAUREEN VARINA | 1 | 64.9% | +41.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18635278 | Antigen Binding Molecules Targeting SARS-CoV-2 | DRISCOLL, MAUREEN VARINA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18635278 | Antigen Binding Molecules Targeting SARS-CoV-2 | DRISCOLL, MAUREEN VARINA | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18635278 | Antigen Binding Molecules Targeting SARS-CoV-2 | DRISCOLL, MAUREEN VARINA | 1644 | §101§102§103§112 | Non-Final OA | — | Pending | Apr 15, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGenerate Biomedicines Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Maureen Varina Driscoll has the most, with 1 of Generate Biomedicines Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
